Information Provided By:
Fly News Breaks for September 23, 2019
Sep 23, 2019 | 07:05 EDT
H.C. Wainwright analyst Yi Chen started Zynex with a Buy rating and $12 price target. The analyst expects the company to remain profitable in the coming quarters. As an established non-pharmaceutical alternative to opioids, electrotherapy using devices such as Zynex's NexWave could alleviate pain without side effects, thus reducing or eliminating the use of opioids and the associated addiction, Chen tells investors in a research note.
News For ZYXI From the Last 2 Days
There are no results for your query ZYXI